{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=54", "query": { "intervention": "pembrolizumab", "page": 54 }, "page_size": 10 }, "pagination": { "page": 54, "page_size": 10, "total_count": 1851, "total_pages": 186, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=55&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=53&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-04T09:29:53.450Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06066333", "title": "Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adrenocortical Carcinoma", "ACC", "Metastatic Adrenocortical Carcinoma" ], "interventions": [ { "name": "Ablative Radiotherapy", "type": "RADIATION" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2023-09-27", "completion_date": "2026-09-27", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06066333" }, { "nct_id": "NCT04379596", "title": "Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Volrustomig", "type": "BIOLOGICAL" }, { "name": "Rilvegostomig", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 452, "start_date": "2020-06-03", "completion_date": "2027-05-04", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04379596" }, { "nct_id": "NCT02858869", "title": "Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Brain", "Metastatic Melanoma", "Mucosal Melanoma", "Ocular Melanoma", "Stage IV Non-Small Cell Lung Cancer", "Stage IV Skin Melanoma", "Melanoma of Unknown Primary" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Stereotactic Radiosurgery", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2016-10-04", "completion_date": "2023-10-28", "has_results": true, "last_update_posted_date": "2026-03-09", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02858869" }, { "nct_id": "NCT03189186", "title": "Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Metastatic Kidney Cancer" ], "interventions": [ { "name": "Pembrolizumab Injection [Keytruda]", "type": "DRUG" }, { "name": "Cryoablation", "type": "PROCEDURE" }, { "name": "Nephrectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of California, Irvine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 0, "start_date": "2017-07-01", "completion_date": "2018-10-17", "has_results": false, "last_update_posted_date": "2021-04-05", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 1, "location_summary": "Orange, California", "locations": [ { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03189186" }, { "nct_id": "NCT03211117", "title": "Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Thyroid Gland Undifferentiated (Anaplastic) Carcinoma" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "OTHER", "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-08-14", "completion_date": "2019-03-28", "has_results": true, "last_update_posted_date": "2020-03-25", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03211117" }, { "nct_id": "NCT03644589", "title": "Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Estrogen Receptor Negative", "HER2/Neu Negative", "Metastatic Breast Cancer", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-04-01", "completion_date": "2022-10-30", "has_results": false, "last_update_posted_date": "2019-04-26", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03644589" }, { "nct_id": "NCT02906332", "title": "Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hackensack Meridian Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 12, "start_date": "2016-12-12", "completion_date": "2022-05", "has_results": true, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02906332" }, { "nct_id": "NCT06516887", "title": "Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Lung Adenocarcinoma" ], "interventions": [ { "name": "bemcentinib", "type": "DRUG" }, { "name": "pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The University of Texas Health Science Center at San Antonio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2024-12-27", "completion_date": "2026-05-21", "has_results": false, "last_update_posted_date": "2026-05-26", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06516887" }, { "nct_id": "NCT05463848", "title": "Surgical Pembro +/- Olaparib w TMZ for rGBM", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "L. Nicolas Gonzalez Castro, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2022-10-21", "completion_date": "2027-03-01", "has_results": false, "last_update_posted_date": "2026-08-24", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 4, "location_summary": "Boston, Massachusetts • New York, New York", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05463848" }, { "nct_id": "NCT02499835", "title": "Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hormone-Resistant Prostate Cancer", "Metastatic Malignant Neoplasm in the Bone", "Metastatic Malignant Neoplasm in the Soft Tissues", "Metastatic Prostate Carcinoma", "Prostate Adenocarcinoma", "Recurrent Prostate Carcinoma", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "pTVG-HP Plasmid DNA Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 66, "start_date": "2015-07-01", "completion_date": "2023-07-27", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-11-04T09:29:53.450Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT02499835" } ] }